# US 2019/0160105 A1 · Methods for selecting improved stem cell for treating intraventricular hemorrhage of premature infants > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0160105 A1 - Document ID: US20190160105A1 - Status: Published application - Kind: A1 - Application number: 16/205,372 - Filed: 2018-11-30 - Published: 2019-05-30 - Earliest claimed: 2017-11-30 - Assignees: Samsung Life Public Welfare Foundation - Applicants: Samsung Life Public Welfare Foundation - Inventors: Yun Sil CHANG; Won Soon PARK; So Yoon AHN; Dong Kyung SUNG - Web page: https://patentgrep.com/patent/US20190160105A1 ## CPC - A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells - A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers - C12N 5/0665: {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood} - G01N 33/5023: {on expression patterns} - G01N 33/5041: {involving analysis of members of signalling pathways} - G01N 33/5073: {Stem cells} - C12N 2501/165: Vascular endothelial growth factor [VEGF] - C12N 2502/081: neurons - C12N 2503/02: Drug screening - C12N 2510/00: Genetically modified cells - G01N 2333/475: Assays involving growth factors - G01N 2800/2871: Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The present disclosure relates to a method for selecting a high efficacy stem cell for treating intraventricular hemorrhage in premature infants, and more particularly, to a method for selecting a high efficacy stem cell for treating intraventricular hemorrhage, including a step of measuring an expression level of a vascular endothelial growth factor (VEGF) and a high efficacy stem cell selected by the method. ## Claims ### Claim 1 A method for selecting a high efficacy stem cell for treating a cerebrovascular disease, the method comprising: measuring an expression level of a vascular endothelial growth factor (VEGF). ### Claim 2 (depends on 1) The method according to claim 1, wherein the method comprises: (a) culturing stem cells; (b) measuring a concentration of a VEGF in a culture solution of the stem cells in Step (a); and (c) evaluating an ability to protect nerve cells based on the measured concentration. ### Claim 3 (depends on 2) The method according to claim 2, wherein the evaluation of the ability to protect nerve cells is determined to be high efficacy when the measured concentration of the VEGF is 50 pg/ml or more. ### Claim 4 (depends on 3) The method according to claim 3, wherein the evaluation of the ability to protect nerve cells is determined to be high efficacy when the measured concentration of the VEGF is 100 pg/ml or more. ### Claim 5 (depends on 1) The method according to claim 1, wherein the cerebrovascular disease is intraventricular hemorrhage (IVH) in a newly born baby. ### Claim 6 (depends on 1) The method according to claim 1, wherein the high efficacy is an ability to protect nerve cells. ### Claim 7 (depends on 1) The method according to claim 1, wherein the stem cell is a stem cell selected from the group consisting of a mesenchymal stem cell, a human tissue-derived mesenchymal stromal cell, a human tissue-derived mesenchymal stem cell, a multipotent stem cell, and an amniotic epithelial cell. ### Claim 8 (depends on 7) The method according to claim 7, wherein the mesenchymal stem cell is derived from umbilical cord, umbilical cord blood, bone marrow, fat, muscles, nerves, skin, amnion, or placenta. ### Claim 9 (depends on 1) A high efficacy stem cell for treating a cerebrovascular disease, which is selected by the method of claim 1. ### Claim 10 (depends on 9) The high efficacy stem cell according to claim 9, wherein the cerebrovascular disease is intraventricular hemorrhage (IVH) in a newly born baby. ### Claim 11 (depends on 9) The high efficacy stem cell according to claim 9, wherein the high efficacy is an ability to protect nerve cells. ### Claim 12 (depends on 9) The high efficacy stem cell according to claim 9, wherein the stem cell is a stem cell selected from the group consisting of a mesenchymal stem cell, a human tissue-derived mesenchymal stromal cell, a human tissue-derived mesenchymal stem cell, a multipotent stem cell, and an amniotic epithelial cell. ### Claim 13 (depends on 12) The high efficacy stem cell according to claim 12, wherein the mesenchymal stem cell is derived from umbilical cord, umbilical cord blood, bone marrow, fat, muscles, nerves, skin, amnion, or placenta. ### Claim 14 (depends on 9) A method for treating a cerebrovascular disease comprising: administering to a subject in need thereof an effective amount of the high efficacy stem cell of claim 9. ### Claim 15 (depends on 14) The method according to claim 14, wherein the cerebrovascular disease is intraventricular hemorrhage (IVH) in a newly born baby. ### Claim 16 (depends on 14) The method according to claim 14, wherein the high efficacy is an ability to protect nerve cells. ### Claim 17 (depends on 14) The method according to claim 14, wherein the stem cell is a stem cell selected from the group consisting of a mesenchymal stem cell, a human tissue-derived mesenchymal stromal cell, a human tissue-derived mesenchymal stem cell, a multipotent stem cell, and an amniotic epithelial cell. ### Claim 18 (depends on 17) The method according to claim 17, wherein the mesenchymal stem cell is derived from umbilical cord, umbilical cord blood, bone marrow, fat, muscles, nerves, skin, amnion, or placenta.